Immunopathology and Therapeutic Strategies in COVID-19

The pathogenesis of COVID-19 reflects a complex interplay between viral replication and host immune responses. In many patients, early innate defences involving macrophages and natural killer cells curb SARS-CoV-2 at mucosal surfaces, but in severe cases these responses become dysregulated, contributing to tissue injury. Lymphopenia, especially of CD4+ and CD8+ T cells, and the emergence of functionally exhausted lymphocytes are hallmarks of critical illness, driven by excessive cytokine release and altered antigen presentation. Persistent low-grade inflammation and transcriptional reprogramming of immune cells have been linked to long-term sequelae. Therapeutic strategies focus on direct antivirals alongside modulation of host immunity. Corticosteroids and targeted cytokine blockade can dampen hyperinflammation, whereas interferon-based therapies aim to restore antiviral signalling. Host-directed approaches, such as repurposed kinase inhibitors, seek to inhibit viral entry and downstream inflammatory cascades. Passive immunotherapies and emerging small molecules continue to be evaluated for their capacity to balance viral control with minimisation of collateral immunopathology.

Research from Nature Portfolio

Recent studies have uncovered mechanisms by which SARS-CoV-2 persists in pulmonary macrophages, revealing that interferon-γ produced by adaptive natural killer cells limits viral reservoirs in the lower airways yet can be subverted by MHC-E-dependent inhibition of NK-cell cytotoxicity. Investigations into T-cell compartments have demonstrated profound shifts in naïve and memory subsets, with terminally differentiated CD8+ T cells exhibiting elevated cytotoxicity alongside markers of exhaustion and senescence. Comparative immunoprofiling of mild and severe cases has highlighted selective loss of CD4+ and CD8+ lymphocytes and dysregulated expression of inhibitory receptors, indicating that aberrant activation of cytotoxic T cells contributes to lung pathology and underlines the rationale for immune-based interventions targeting checkpoint pathways.

Immunopathology and Therapeutic Strategies in COVID-19 publication trend

The graph below shows the total number of articles in immunopathology and therapeutic strategies in covid-19 across all publications each year (not limited to Nature Index journals).

Technical terms

Lymphopenia: Reduction in circulating lymphocyte numbers, often marking severe COVID-19.

Cytokine storm: Excessive release of pro-inflammatory mediators that drive tissue damage.

T-cell exhaustion: Functional impairment of T lymphocytes characterised by inhibitory receptor expression.

Natural killer (NK) cells: Innate effector lymphocytes that mediate early antiviral responses.

Interferon-γ (IFN-γ): Cytokine critical for antiviral immunity and macrophage activation.

References

1. SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells. Nature Immunology (2023).
2. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nature Communications (2020).
3. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature Communications (2020).
4. Single-cell spatiotemporal analysis of the lungs reveals Slamf9+ macrophages involved in viral clearance and inflammation resolution. Cell Discovery (2024).
5. SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile. Genome Medicine (2023).
6. Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects. Journal of Clinical Investigation (2023).